A
Alcista
Alcista · 25%ACRS
$0.91
Precio del escenario
$3.480
+0.212 (+6.10%)Al cierre
Loading chart…
- Máximo
- 3.500
- Apertura
- 3.280
- Precio medio ponderado por volumen
- 3.41
- Volumen
- 1.75M
- Capitalización
- 79.10M
- Mínimo
- 3.255
- Importe
- 5.96M
- EV/EBITDA, TTM
- -6.34
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Análisis de IA of Aclaris Therapeutics, Inc. (ACRS)
ComprarAclaris Therapeutics Inc is a good buy right now due to its current price of $3.28, which is significantly below analyst price targets of $10 and $13. The RSI is at 24.444, indicating that the stock is oversold, suggesting a potential rebound. Additionally, the company has a strong cash position of $170.6 million, which can support its upcoming clinical trials, providing a solid foundation for future growth. However, the main risk is the ongoing net losses, which reached $21.5 million in Q2 2026, indicating financial strain that could affect investor confidence.
Recomendaciones de analistas (6)
+225.57% de potencial alcista
Comprar
6 Comprar
0 Mantener
0 Vender
Actual: 3.48
Mínimo
8.00
Promedio
11.33
Máximo
16.00
Canaccord
Comprar
$10
2026-09-01
Canaccord
2026-09-01
Precio objetivo
$10
Comprar
Piper Sandler
Sobreponderar
$11
2026-05-05
Piper Sandler
2026-05-05
Precio objetivo
$11
Sobreponderar
Guggenheim
Comprar
$12
2026-05-05
Guggenheim
2026-05-05
Precio objetivo
$12
Comprar
Wedbush
Superar al mercado
$10
2026-04-29
Wedbush
2026-04-29
Precio objetivo
$10
Superar al mercado
Oppenheimer
Superar al mercado
$10
2026-04-16
Oppenheimer
2026-04-16
Precio objetivo
$10
Superar al mercado
Métricas de valoración
El PER previsto actual de Aclaris Therapeutics, Inc. (ACRS) es 0.00, frente a su media de 5 años de -5.21.
Escenarios de precio de Alphio AI para ACRS
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con ACRS en cartera
Cronología de eventos
Noticias
9.508-07NASDAQ.COMAclaris Reports Wider Net Loss in Q2, Receives FDA Fast Track Designation
9.008-06GlobenewswireAclaris Receives FDA Fast Track Designation for Modzatinib
9.008-06NewsfilterAclaris Receives FDA Fast Track Designation for Modzatinib
- 9.508-06seekingalpha
Aclaris Reports Q2 Earnings Beat Expectations
9.508-06NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Earnings
Preguntas frecuentes sobre ACRS, respondidas por Alphio AI
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Aclaris Therapeutics Inc is a good buy right now due to its current price of $3.28, which is significantly below analyst price targets of $10 and $13. The RSI is at 24.444, indicating that the stock is oversold, suggesting a potential rebound. Additionally, the company has a strong cash position of $170.6 million, which can support its upcoming clinical trials, providing a solid foundation for future growth. However, the main risk is the ongoing net losses, which reached $21.5 million in Q2 2026, indicating financial strain that could affect investor confidence.
6 analysts cover ACRS: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.33.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.